Stoke Therapeutics Adopts Key Proposals at Annual Meeting

Stoke Therapeutics ( (STOK) ) has provided an announcement.

On June 3, 2025, Stoke Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were adopted. These included the election of three Class III directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, and the approval of executive compensation and its future advisory vote frequency. These decisions are expected to influence the company’s governance and operational strategies moving forward.

The most recent analyst rating on (STOK) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.

Spark’s Take on STOK Stock

According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.

Stoke Therapeutics has strong technical indicators and corporate events supporting its stock, but its unprofitability and negative cash flow weigh down the overall score. The stock is reasonably valued, indicating potential for growth if profitability and cash flow improve.

To see Spark’s full report on STOK stock, click here.

More about Stoke Therapeutics

Stoke Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for genetic diseases. The company is known for its innovative RNA-based therapies aimed at addressing the underlying causes of severe diseases.

Average Trading Volume: 833,574

Technical Sentiment Signal: Buy

Current Market Cap: $541.1M

Find detailed analytics on STOK stock on TipRanks’ Stock Analysis page.